Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
